Suppr超能文献

YAP 和 TAZ 介导的肝星状细胞增殖有助于肝缺血再灌注损伤后的肝修复和再生。

Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.

机构信息

Department of Surgery, University of Cincinnati, College of Medicine , Cincinnati, Ohio.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G471-G482. doi: 10.1152/ajpgi.00153.2017. Epub 2018 Jan 11.

Abstract

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of cell proliferation and organ size; however, their physiological contribution after liver injury has not been fully understood. In this study, we sought to determine the role of YAP and TAZ during liver recovery after ischemia-reperfusion (I/R). A murine model of partial (70%) I/R was used to induce liver injury and study the reparative and regenerative response. After liver injury, there was marked activation and proliferation of hepatic stellate cells. The Hippo pathway components, large tumor suppressor 1 (LATS1) and its adapter protein, Mps one binder 1 (MOB1), were inactivated during liver repair, and YAP and TAZ were activated selectively in hepatic stellate cells. Concurrently, the expression of connective tissue growth factor and survivin, both of which are YAP and TAZ target genes, were upregulated. Hepatic stellate cell expansion and concomitant activation of YAP and TAZ occurred only in the injured liver and were not observed in the nonischemic liver. Treatment of mice with verteporfin, an inhibitor of YAP and TAZ, decreased hepatic stellate cell proliferation, survivin, and cardiac ankyrin repeat protein expression. These changes were associated with a significant decrease in hepatocyte proliferation. The data suggest that liver repair and regeneration after I/R injury are dependent on hepatic stellate cell proliferation, which is mediated by YAP and TAZ. NEW & NOTEWORTHY This study is the first to assess the proliferation of hepatic stellate cells (HSCs) after ischemia-reperfusion (I/R) injury and their role in the reparative and regenerative process. Here we show that the Hippo pathway is inactivated after I/R and that Yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) activation is detected in HSC. HSC proliferation and expansion are prominent during liver recovery after I/R injury. Inhibition of YAP/TAZ activation with verteporfin reduces HSC proliferation and target gene expression and attenuates hepatocyte proliferation.

摘要

Yes 相关蛋白 (YAP) 和含 PDZ 结合基序的转录共激活因子 (TAZ) 是细胞增殖和器官大小的关键调节因子;然而,它们在肝损伤后的生理贡献尚未完全了解。在这项研究中,我们试图确定 YAP 和 TAZ 在肝缺血再灌注 (I/R) 后恢复期间的作用。使用部分 (70%) I/R 的小鼠模型诱导肝损伤并研究修复和再生反应。肝损伤后,肝星状细胞明显活化和增殖。Hippo 通路成分,大肿瘤抑制因子 1 (LATS1) 和其衔接蛋白,Mps 结合蛋白 1 (MOB1),在肝修复过程中失活,YAP 和 TAZ 选择性地在肝星状细胞中激活。同时,结缔组织生长因子和存活素的表达上调,它们都是 YAP 和 TAZ 的靶基因。肝星状细胞扩张以及 YAP 和 TAZ 的伴随激活仅发生在受损的肝脏中,而在非缺血的肝脏中未观察到。用维替泊芬 (verteporfin) 治疗小鼠,维替泊芬是 YAP 和 TAZ 的抑制剂,可减少肝星状细胞增殖、存活素和心脏锚蛋白重复蛋白的表达。这些变化与肝细胞增殖显著减少有关。数据表明,I/R 损伤后肝修复和再生依赖于肝星状细胞增殖,这是由 YAP 和 TAZ 介导的。本研究首次评估了缺血再灌注 (I/R) 损伤后肝星状细胞 (HSCs) 的增殖及其在修复和再生过程中的作用。在这里,我们表明 Hippo 通路在 I/R 后失活,并且在 HSC 中检测到 Yes 相关蛋白/转录共激活因子与 PDZ 结合基序 (YAP/TAZ) 激活。在 I/R 损伤后肝恢复期间,HSC 增殖和扩张明显。用维替泊芬抑制 YAP/TAZ 激活可减少 HSC 增殖和靶基因表达,并减弱肝细胞增殖。

相似文献

1
Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G471-G482. doi: 10.1152/ajpgi.00153.2017. Epub 2018 Jan 11.
3
Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells.
Mol Immunol. 2019 Mar;107:29-40. doi: 10.1016/j.molimm.2019.01.004. Epub 2019 Jan 11.
4
Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury.
J Hepatol. 2019 Oct;71(4):719-730. doi: 10.1016/j.jhep.2019.05.029. Epub 2019 Jun 13.
5
Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration.
Theranostics. 2019 May 31;9(13):3840-3852. doi: 10.7150/thno.33370. eCollection 2019.
6
A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Genes Dev. 2015 Jun 15;29(12):1271-84. doi: 10.1101/gad.262816.115.
7
Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells.
Gastroenterology. 2018 Apr;154(5):1465-1479.e13. doi: 10.1053/j.gastro.2017.12.022. Epub 2018 Jan 3.

引用本文的文献

1
Modelling the liver's regenerative capacity across different clinical conditions.
JHEP Rep. 2025 May 30;7(8):101465. doi: 10.1016/j.jhepr.2025.101465. eCollection 2025 Aug.
4
Deciphering ferroptosis in critical care: mechanisms, consequences, and therapeutic opportunities.
Front Immunol. 2024 Dec 16;15:1511015. doi: 10.3389/fimmu.2024.1511015. eCollection 2024.
5
TAZ deficiency impairs the autophagy-lysosomal pathway through NRF2 dysregulation and lysosomal dysfunction.
Int J Biol Sci. 2024 Apr 22;20(7):2592-2606. doi: 10.7150/ijbs.88897. eCollection 2024.
6
Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology.
Hepatol Commun. 2024 Apr 12;8(5). doi: 10.1097/HC9.0000000000000411. eCollection 2024 May 1.
7
Survivin inhibition ameliorates liver fibrosis by inducing hepatic stellate cell senescence and depleting hepatic macrophage population.
J Cell Commun Signal. 2024 Jan 25;18(1):e12015. doi: 10.1002/ccs3.12015. eCollection 2024 Mar.
8
Endothelial YAP/TEAD1-CXCL17 signaling recruits myeloid-derived suppressor cells against liver ischemia-reperfusion injury.
Hepatology. 2025 Mar 1;81(3):888-902. doi: 10.1097/HEP.0000000000000773. Epub 2024 Feb 26.
9
Signaling pathways of liver regeneration: Biological mechanisms and implications.
iScience. 2023 Dec 7;27(1):108683. doi: 10.1016/j.isci.2023.108683. eCollection 2024 Jan 19.
10
YAP/TAZ: Molecular pathway and disease therapy.
MedComm (2020). 2023 Aug 9;4(4):e340. doi: 10.1002/mco2.340. eCollection 2023 Aug.

本文引用的文献

3
Non-Photoinduced Biological Properties of Verteporfin.
Curr Med Chem. 2016;23(11):1171-84. doi: 10.2174/0929867323666160316125048.
4
Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies.
Cell Mol Immunol. 2016 May;13(3):316-27. doi: 10.1038/cmi.2015.104. Epub 2016 Feb 24.
5
Mechanisms of Hippo pathway regulation.
Genes Dev. 2016 Jan 1;30(1):1-17. doi: 10.1101/gad.274027.115.
6
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.
Cell. 2015 Nov 5;163(4):811-28. doi: 10.1016/j.cell.2015.10.044.
7
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.
J Hepatol. 2015 Sep;63(3):679-88. doi: 10.1016/j.jhep.2015.04.011. Epub 2015 Apr 20.
8
CXC chemokines function as a rheostat for hepatocyte proliferation and liver regeneration.
PLoS One. 2015 Mar 10;10(3):e0120092. doi: 10.1371/journal.pone.0120092. eCollection 2015.
9
Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration.
Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G196-204. doi: 10.1152/ajpgi.00077.2014. Epub 2014 May 29.
10
Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice.
Hepatol Res. 2015 Mar;45(3):305-14. doi: 10.1111/hepr.12352. Epub 2014 Jun 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验